|1.||Brinton, Roberta Diaz: 12 articles (01/2015 - 02/2006)|
|2.||Stein, Donald G: 10 articles (11/2010 - 01/2004)|
|3.||Hirst, Jonathan J: 9 articles (02/2014 - 12/2002)|
|4.||Wang, Jun Ming: 9 articles (08/2012 - 02/2006)|
|5.||Walker, David W: 9 articles (01/2012 - 12/2002)|
|6.||Casarosa, Elena: 9 articles (01/2011 - 03/2002)|
|7.||Bäckström, Torbjörn: 8 articles (11/2015 - 10/2005)|
|8.||Rogawski, Michael A: 8 articles (08/2015 - 07/2004)|
|9.||Luisi, Stefano: 8 articles (01/2011 - 02/2002)|
|10.||Petraglia, F: 8 articles (01/2011 - 03/2000)|
01/01/2007 - "Pregnanolone afforded protection against seizures with larger effects during EW than in control conditions and greater effects in female than male rats. "
08/01/2005 - "The male C57BL/6J mice had to be removed from the study due to increased seizures apparently associated with the chronic intermittent pregnanolone administration used in drug discrimination. "
02/01/2005 - "In the present study we investigated the post-ictal serum allopregnanolone levels in children with partial seizures and generalized seizures, respectively. "
12/15/2015 - "In contrast, allopregnanolone at a low dose markedly shielded neonatal rats against PTZ convulsions. "
12/15/2015 - "Allopregnanolone only at the higher dose extended the latency of 4-aminopyridine-induced seizures. "
|2.||Alzheimer Disease (Alzheimer's Disease)
02/01/2014 - "Investigation of allopregnanolone as a regenerative therapeutic has provided key insights into mechanistic targets for neurogenesis and disease modification, dosing requirements, optimal treatment regimen, route of administration and the appropriate formulation necessary to advance to proof of concept clinical studies to determine efficacy of allopregnanolone as a regenerative and disease modifying therapeutic for Alzheimer's disease. "
01/01/2015 - "To develop allopregnanolone as a therapeutic for Alzheimer's disease, we investigated multiple formulations and routes of administration in translationally relevant animal models of both sexes. "
02/01/2014 - "Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise."
04/01/2013 - "Therapeutic windows for efficacy of allopregnanolone were evident in the brains of mice with both normal ageing and Alzheimer disease. "
01/01/2015 - "Correction: Allopregnanolone Preclinical Acute Pharmacokinetic and Pharmacodynamic Studies to Predict Tolerability and Efficacy for Alzheimer's Disease."
|3.||Weight Loss (Weight Reduction)
11/01/2008 - "Pretreatment with allopregnanolone (10 and 20 mg/kg i.p.) significantly improved locomotor activity, weight loss and anxiety-like behavior. "
12/15/2005 - "We have investigated the effects of allopregnanolone treatments on survival, weight loss, motor function, magnetic resonance imaging (MRI), and neuropathology in the mouse model of NPC (Npc1(-/-) mice). "
12/15/2005 - "The effects on survival and weight loss of a single injection on day 7 followed by injections every 2 weeks were also evaluated in Npc1(-/-) mice, and the beneficial effects were found to be greater than with the single injection at day 7. We conclude that allopregnanolone treatment significantly ameliorates several symptoms of NPC in Npc1(-/-) mice, presumably by effects on myelination or neuronal connectivity."
11/01/2008 - "A combination of flumazenil (0.5 mg/kg) and picrotoxin (0.5 mg/kg) with allopregnanolone (10 mg/kg) antagonized the protective effect of allopregnanolone and caused further impairment in locomotor activity, anxiety-like behavior, weight loss and oxidative damage. "
|4.||Diabetic Neuropathies (Diabetic Neuropathy)
|5.||Premenstrual Syndrome (Premenstrual Tension)
10/01/2002 - "Allopregnanolone levels and symptom improvement in severe premenstrual syndrome."
10/01/2005 - "The primary aim of this study was to investigate possible alcohol-induced changes in allopregnanolone serum concentrations across different menstrual cycle phases in women with severe premenstrual syndrome (PMS) and controls. "
10/01/2002 - "These preliminary results offer the first placebo-controlled evidence of association between allopregnanolone levels and premenstrual syndrome treatment response and suggest the importance of further study of the associations of allopregnanolone with premenstrual syndromes and the role of allopregnanolone in response to antidepressant medications."
10/01/2002 - "The aim of this study was to determine the association of allopregnanolone levels with improvement of mood and behavioral symptoms following antidepressant treatment for severe premenstrual syndrome. "
10/01/1999 - "This study has evaluated the effects of pregnanolone administration on part of the hypothalamus-pituitary-gonadal (HPG) axis throughout the menstrual cycle in control subjects and patients with premenstrual syndrome (PMS). "
|1.||GABA-A Receptors (GABA(A) Receptor)
|2.||gamma-Aminobutyric Acid (GABA)
|4.||Neurotransmitter Agents (Neurotransmitter)
|6.||Ethanol (Ethyl Alcohol)
|4.||Drug Therapy (Chemotherapy)